ClinicalTrials.gg
WithdrawnNCT04440891TMS_ADUpdated Aug 14, 2023

Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease

An interventional study of TMS stimulation with X-Torp task and TMS-Stimulation with MindMotion Go in Alzheimer Disease, sponsored by Ali Rezai. Withdrawn at 1 site in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Ali Rezai · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Difficulty with recruitment due to Covid. 3 subjects consented but did not start any study procedures or participate in the study.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2019, registered May 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,578th of 1,610
0 · median 73
Started
2019
with 117 others
No phase
610 of 1,941
131 open now
Registered
1,196th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,578th largest by enrollment of the 1,610 interventional ones that give a count, is one of 118 that started in 2019, is one of 610 with no phase, and was the 1,196th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a randomized sham control study to evaluate how repetitive Transcranial Magnetic Stimulation (rTMS), interactive cognitive training, or the combination of rTMS and cognitive training reduce the cognitive decline of patients diagnosed with Alzheimer's disease

Read the detailed description

Participants may be assigned to one of four experimental arms (1-TMS-Stimulation with X-Torp task, 2-TMS-Stimulation with MindMotion Go, 3-TMS-Sham with X-Torp task, 4-TMS-Sham with MindMotion Go.) The study will be conducted in two phases. During Phase 1, participants will be randomized between experimental conditions 1 and 4. Data will be analyzed upon completion of Phase1 and Phase 2 will commence only if there is efficacy in the TMS arm. During Phase2, participants will be randomized to arms 2 and 3.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or Female between 50-85 years of age

  • Able and willing to give
  • Probable AD consistent with NIA/AA criteria
  • Modified Hachinski Ischemia Scale (MHIS) score of \<= 4
  • Geriatric Depression Scale (GDS) score of \<= 6
  • (MMSE) score 18-26. The MMSE adjusted scoring instructions may be followed for screening patients as applicable.

Exclusion criteria

Exclusion Criteria:

  • Unstable medical conditions
  • Visual impairments
  • Mobility limitations
  • Cognition-enhancing medication unless on a stable dosage for at least 3 months before the start of the trial.
  • History of epilepsy or seizure disorder
  • History of psychosis
  • Current thoughts of suicidal ideation or self-harm as assessed by the Columbia-Suicide severity rating scale score
  • Progressive neurological disorder or focal signs of abnormality on neurological exam as conducted by a neurologist (other than current diagnosis of AD)
  • Tinnitus
  • Metal implants (excluding dental fillings)
  • Possible pregnancy
  • Substance use disorder within the past six months
  • Have other mental or physical conditions that are inappropriate for study participation at PI's or delegated sub investigator's discretion.
  • Intake of one or a combination of the drugs that may due to their significant seizure threshold lowering potential
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TMS-Stimulation with X-Torp task

    TMS with VR 1 experimental arm

    Device: TMS stimulation with X-Torp task

  • Experimental
    TMS-Stimulation with MindMotion Go

    TMS with VR 2 experimental arm

    Device: TMS-Stimulation with MindMotion Go

  • Sham comparator
    TMS-Sham with X-Torp task

    TMS sham control with VR 1

    Device: TMS-Sham with X-Torp task

  • Sham comparator
    TMS-Sham with MindMotion Go

    TMS sham control with sham VR 2

    Device: TMS-Sham with MindMotion Go

Interventions

  • DeviceTMS stimulation with X-Torp task

    TMS-Stimulation with X-Torp task

  • DeviceTMS-Stimulation with MindMotion Go

    TMS-Stimulation with MindMotion Go

  • DeviceTMS-Sham with X-Torp task

    TMS-Sham with X-Torp task

  • DeviceTMS-Sham with MindMotion Go

    TMS-Sham with MindMotion Go

06

What researchers measure

Primary outcomes

  1. Cognitive Performance

    Change in cognitive task performance over time using the total score on the Mini Mental State Examination (range 0-30)

    Time frame: 6 months after completion study procedure

Secondary outcomes

  1. Brain MRI

    Change in brain structure and function over time

    Time frame: 6 months after completion of study procedure compared to screening

  2. Memory Performance

    Total recall on the California Verbal Learning Test - short form (range 0-36)

    Time frame: 6 months after completion of study procedure compared to screening

07

Study locations

1 site
  • West Virginia University Rockefeller Neuroscience Institute
    Morgantown, West Virginia 26506, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Nov 2021, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2020
First posted
Jun 22, 2020
StartActual
Oct 3, 2019
Primary completionActual
Nov 2, 2021
CompletionActual
Nov 2, 2021
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04440891
Lead sponsor
Ali Rezai
Responsible party
Ali Rezai (Director, West Virginia University) — Sponsor-investigator
First posted
Jun 22, 2020
Start date
Oct 3, 2019
Primary completion
Nov 2, 2021
Completion
Nov 2, 2021
Last update
Aug 14, 2023

Study contacts

Marc Haut, PhD
study chair · Rockefeller Neuroscience Institute
Victor Finomore, PhD
study director · Rockefeller Neuroscience Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion